All News
Infection or Disease Flare: What Tools Can Help Differentiate?
Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult. Few studies have evaluated potential differentiators; and having such tools would meet a huge unmet need.
Read Article
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
How Should Patients With Autoimmune Diseases Approach COVID Vaccination?
Healthcare is a personal and individualized relationship between a provider and patient. Each patient is treated according to their particular symptoms and personal health characteristics.
Read Article
RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.
Read Article
CRESS – A New Composite Measure for Primary Sjögren's Syndrome
Randomized clinical trials in primary Sjögren's syndrome (pSS) are fraught with fault and inconclusive outcome measures, including the more recently developed EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). There's a new composite endpoint outcome for RCTs in pSS, called the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS).
Read Article
Potential Birth Defects with Hydroxychloroquine
Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.
Read Article
Links:
Do B-cell targeted therapies still have a place for the treatment of Sjogren’s?
B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy with rituximab in Phase II trials and case series, it failed to meet its primary endpoint when investigated in two Phase III trials. It is worth noting that the primary endpoint used in both trials was a subjective measure. Post-hoc analyses however showed greater improvement in objective measures such as salivary flow rate and salivary gland ultrasound score in RTX-treated group vs placebo.
Therefore, do B-cell targeted therapies still have a place for the treatment of pSS?
Links:
Links:
Can the Focus Score predict Lymphoma in Sjogren’s syndrome?
Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder.
Read Article
Links:
Eric Dein ejdein1 ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)